Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M293Revenue (TTM) $M1.9Net Margin (%)-2,620.1Altman Z-Score2.9
Enterprise Value $M230EPS (TTM) $-1.9Operating Margin %-2,546.7Piotroski F-Score2
P/E(ttm)--Beneish M-Score-0.1Pre-tax Margin (%)-2,620.1Higher ROA y-yY
Price/Book4.510-y EBITDA Growth Rate %--Quick Ratio9.6Cash flow > EarningsY
Price/Sales1355-y EBITDA Growth Rate %--Current Ratio9.6Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-56.9Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-75.9Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M29.0ROIC % (ttm)-4,902.8Gross Margin Increase y-yN

Gurus Latest Trades with OCUL

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

OCUL is held by these investors:



OCUL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sawhney AmarpreetPresident and CEO, 10% Owner 2016-12-15Buy45,300$7.8530.06view
Sawhney AmarpreetPresident and CEO, 10% Owner 2016-06-09Buy10,000$6.752.39view
Sawhney AmarpreetPresident and CEO, 10% Owner 2015-11-17Buy10,000$8.2523.76view
Fortune JamesCOO 2015-09-15Sell9,470$17.16-40.5view
Sawhney AmarpreetPresident and CEO, 10% Owner 2015-09-14Buy15,000$16.5-38.12view
Versant Venture Capital III, L10% Owner 2015-06-15Sell320,000$22-53.59view
Warden Charles MDirector, 10% Owner 2015-06-15Sell320,000$22-53.59view
SVLSF IV, LLC10% Owner 2015-06-10Sell1,119,000$22-53.59view
Versant Venture Capital III, L10% Owner 2015-06-10Sell427,000$22-53.59view
Warden Charles MDirector, 10% Owner 2015-06-10Sell427,000$22-53.59view

Quarterly/Annual Reports about OCUL:

    News about OCUL:

    Articles On GuruFocus.com
    Weekly CEO Buys Highlight: APD, OCUL, CNMD, OPK, AEGR Aug 04 2014 

    More From Other Websites
    Ocular Therapeutix™ Presented Phase 3 Data for DEXTENZA™ at the Association for Research in... May 11 2017
    Ocular Therapeutix™ Presents Preclinical Data on Pharmacokinetics, Efficacy and Tolerability of... May 09 2017
    Why Ocular Therapeutix Inc Stock Jumped Higher Today May 08 2017
    Betting on Adamis Pharmaceuticals and Ocular Therapeutix Ahead of FDA Decisions May 08 2017
    Today's Research Reports on Stocks to Watch: ImmunoGen and Ocular Therapeutix May 08 2017
    Ocular Therapeutix™ Presents Additional Phase 3 Data and Patient Reported Outcomes Results for... May 08 2017
    Edited Transcript of OCUL earnings conference call or presentation 5-May-17 12:30pm GMT May 06 2017
    Why Ocular Theraputix Inc. Got Hammered Today May 05 2017
    Ocular Therapeutix reports 1Q loss May 05 2017
    Investor Network: Ocular Therapeutix Inc to Host Earnings Call May 05 2017
    Ocular Therapeutix™ Reports First Quarter 2017 Financial Results May 05 2017
    Ocular Therapeutix™ to Present Data on Anterior and Posterior Segment Drug Product Candidates at... May 02 2017
    Ocular Therapeutix™ to Report First Quarter 2017 Financial Results May 01 2017
    ETFs with exposure to Ocular Therapeutix, Inc. : April 24, 2017 Apr 24 2017
    Ocular Therapeutix™ to Present Additional Phase 3 Data and Patient Reported Outcomes Results for... Apr 24 2017
    Ocular Therapeutix™ Appoints George Migausky as Interim Chief Financial Officer Apr 06 2017
    Ocular Therapeutix, Inc. :OCUL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
    Positive Results Reported For Ocular Therapeutix Inc (OCUL) Dextenza Following Phase III Study Mar 17 2017
    Why Ocular Therapeutix Inc Saw its Share Price Jump Today Mar 16 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

    GF Chat